康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06185 康希诺生物

开市前 04-11 09:28:57

28.800

+0.400

+1.41%

最高28.800	最低28.800	成交量400.00
今开28.800	昨收28.400	日振幅0.00%
总市值71.27亿	流通市值38.30亿	总股本2.47亿
成交额1.15万	换手率0.00%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":28.8,"timestamp":1744334434009,"preClose":28.4,"halted":0,"volume":400,"delay":0,"floatShares":133000000,"shares":247449899,"eps":-1.6250612083410911,"marketStatus":"开市前","change":0.4,"latestTime":"04-11 09:28:57","open":28.8,"high":28.8,"low":28.8,"amount":11520,"amplitude":0,"askPrice":28.8,"askSize":1400,"bidPrice":28.5,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.6250612083410911,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744335000000},"marketStatusCode":1,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":28.4,"dividendRate":0.031357,"openAndCloseTimeList":[[1744335000000,1744344000000],[1744347600000,1744358400000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":54.08,"timestamp":1744334936000,"preClose":54.78,"halted":0,"volume":4900,"delay":0,"premium":"-49.86"}},"requestUrl":"/m/hq/s/06185","defaultTab":"news","newsList":[{"id":"2518137012","title":"全国政协委员、康希诺生物首席科学官朱涛：我国正处于疫苗研发的“黄金十年”，免疫规划体系将持续完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2518137012","media":"21经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518137012?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:37","pubTimestamp":1741595820,"startTime":"0","endTime":"0","summary":"然而，随着疫苗种类的增多，传染病种类的变化，扩大免疫规划疫苗种类的呼声越来越高。全国政协委员、康希诺生物首席科学官朱涛在接受南方财经全媒体集团全国两会报道组记者采访时表示，从2020年往后十年，可以说是疫苗供应端、研发端的“黄金十年”，一系列的品种都有望在这10年上市。朱涛表示，具体纳入哪些疫苗，要计算纳入疫苗以后对公共卫生有多大受益。2021年，康希诺生物的4价流脑结合疫苗获批，又填补了一项空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031016461598a25800&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031016461598a25800&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","688185","06185","BK1191","BK1515"],"gpt_icon":0},{"id":"2518471790","title":"康希诺朱涛：mRNA肿瘤疫苗是布局方向，国家免疫规划扩容需考虑供应稳定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2518471790","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518471790?lang=zh_cn&edition=full","pubTime":"2025-03-09 08:35","pubTimestamp":1741480551,"startTime":"0","endTime":"0","summary":"mRNA技术平台可应用于多类生物制品的开发，包括肿瘤领域及免疫治疗也可以是拓展方向。近两年，呼吁将某些二类疫苗纳入国家免疫规划的声音不断出现。对此，朱涛认为，具体纳入哪些疫苗或者先纳入哪一个，背后需要详细的计算，纳入后到底能带来多大的公共卫生收益，这不仅要考虑价格，还要考虑供应的稳定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309085913a2675d92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309085913a2675d92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06185","BK1515","BK1191","688185","BK1161"],"gpt_icon":0},{"id":"2517740691","title":"智通AH统计|3月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2517740691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517740691?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:15","pubTimestamp":1741335307,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止3月7日收盘，东北电气、安德利果汁、弘业期货分列AH溢价率前三位，溢价率分别为864.29%、328.78%、325.29%；招商银行、药明康德、美的集团分列AH溢价率末三位，溢价率分别为7.49%、13.27%、16.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03143","00187","00347","HYDD.SI","399300","00568","03968","01812","002594","03606","BK1119","01658","01330","03145","00553","BYDDY","01877","HPAD.SI","02883","81211","601318","01349","01528","LU2048586759.USD","02899","02359","00042","02727","01057","06185","06127","159982","688981","03678","02218","02338","00995","02628","06690","00300","06680","PNGAY","01033","06881","82318","00177"],"gpt_icon":1},{"id":"2517777972","title":"康希诺生物盘中异动 大幅上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517777972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517777972?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:40","pubTimestamp":1741225255,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时40分，康希诺生物股票出现波动，股价大幅拉升5.00%。截至发稿，该股报37.800港元/股，成交量52.14万股，换手率0.39%，振幅3.33%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康希诺生物股票所在的生物技术行业中，整体涨幅为0.93%。康希诺生物公司简介：许可项目:第三类医疗器械经营;药品生产;药品进出口;药品零售;药品批发;货物进出口;技术进出口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094055abea71f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094055abea71f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","BK0239","06185"],"gpt_icon":0},{"id":"2516212625","title":"康希诺生物03月04日遭主力抛售170万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516212625","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516212625?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:38","pubTimestamp":1741081110,"startTime":"0","endTime":"0","summary":"03月04日, 康希诺生物股价跌1.51%，报收35.90元，成交金额4571万元，换手率0.96%，振幅4.66%，量比0.36。康希诺生物今日主力资金净流出170万元，连续3日净流出，上一交易日主力净流出203万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为3.92%。该股近5个交易日下跌3.48%，主力资金累计净流入871万元；近20日主力资金累计净流入4828万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174311abe792c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174311abe792c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","BK1574","06185","BK1515"],"gpt_icon":0},{"id":"2516651641","title":"全国政协委员、康希诺生物首席科学官朱涛：希望通过政策优化医药创新生态 支持医药创新成果转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2516651641","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516651641?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:20","pubTimestamp":1741022430,"startTime":"0","endTime":"0","summary":"医药创新成果的转化效率，直接关系着人民的生命健康。目前，医药创新成果转化过程较为复杂，涉及科研机构、企业、监管部门等多个主体，现有的部分政策和机制一定程度上制约了成果转化的效率。为此，希望通过政策优化医药创新生态、支持医药创新成果转化，可以在审批流程上进行改进，提高疫苗等新药上市转化效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335164351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335164351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","09939","BK1161","06185","BK1191","BK1574"],"gpt_icon":0},{"id":"2516868398","title":"康希诺：mRNA技术平台可应用于多类生物制品的开发，包括肿瘤领域及免疫治疗也可以是拓展方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2516868398","media":"互动易","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516868398?lang=zh_cn&edition=full","pubTime":"2025-03-03 17:09","pubTimestamp":1740992941,"startTime":"0","endTime":"0","summary":"有投资者向康希诺提问， 贵公司上海康希诺的定位是什么？疫苗+药品是公司唯一壮大的途径，上海康希诺未来是否向创新肿瘤药和创新免疫药方面发展？谢谢。公司回答表示，尊敬的投资人您好，康希诺上海子公司主要为mRNA技术等前沿技术的探索与技术积累转化而设立。mRNA技术平台可应用于多类生物制品的开发，包括肿瘤领域及免疫治疗也可以是拓展方向。现阶段公司将在做好主营业务的基础上进行延展探索。未来如有阶段性进展，将及时分享。谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303171942a25cddb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303171942a25cddb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","BK1191","BK1161","BK1515","BK1574","06185"],"gpt_icon":0},{"id":"2516501421","title":"智通AH统计|3月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2516501421","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516501421?lang=zh_cn&edition=full","pubTime":"2025-03-03 16:15","pubTimestamp":1740989707,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止3月3日收盘，东北电气、浙江世宝、京城机电股份分列AH溢价率前三位，溢价率分别为900.00%、343.84%、338.81%；招商银行、比亚迪股份、美的集团分列AH溢价率末三位，溢价率分别为11.44%、18.66%、19.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01349","01877","00981","01812","BK1607","688981","00995","159982","BYDDY","00568","00187","02899","01658","06690","02465","02359","03678","02338","00300","IE0008368742.USD","01211","399300","00347","00553","LU0067412154.USD","02628","00042","01057","HYDD.SI","02218","03968","06127","02727","IE00B29SXG58.USD","00038","03143","LU2148510915.USD","03606","06185","LU1064131003.USD","01528","06680","01033","06869","002594","81211","00338","01108","03328"],"gpt_icon":1},{"id":"2514145533","title":"智通AH统计|2月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2514145533","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514145533?lang=zh_cn&edition=full","pubTime":"2025-02-28 16:15","pubTimestamp":1740730506,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止2月28日收盘，东北电气、浙江世宝、安德利果汁分列AH溢价率前三位，溢价率分别为938.46%、348.25%、342.33%；招商银行、比亚迪股份、美的集团分列AH溢价率末三位，溢价率分别为10.70%、16.63%、18.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["81211","399300","01108","00038","01057","00323","02465","01658","00042","01211","02202","LU0163747925.USD","00338","01033","BYDDY","00300","00995","02899","06869","688981","159982","000002","03678","02338","01349","03968","06881","03606","HYDD.SI","02359","LU1152091168.USD","00568","01812","02727","06185","00553","00187","06690","002594","01877","06680","BK1110","LU0862451753.SGD","06127","02218","06936","03143"],"gpt_icon":1},{"id":"2514836913","title":"港股异动 | 康希诺生物(06185)盘中跌近5% 年度归母净亏损3.79亿元，同比收窄74.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836913","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514836913?lang=zh_cn&edition=full","pubTime":"2025-02-28 09:55","pubTimestamp":1740707738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物盘中跌近5%，截至发稿，跌4.84%，报39.3港元，成交额2126.29万港元。消息面上，2月27日，康希诺生物发布2024年度业绩快报，营业总收入8.46亿元，同比增长137.01%；归属于母公司所有者的净亏损3.79亿元，同比收窄74.45%；基本每股亏损1.53元。因此，集团营业收入较去年同期大幅增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK1161","BK1191","06185"],"gpt_icon":0},{"id":"2514690973","title":"康希诺生物盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514690973","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514690973?lang=zh_cn&edition=full","pubTime":"2025-02-28 09:53","pubTimestamp":1740707587,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时53分，康希诺生物股票出现波动，股价快速跳水5.08%。截至发稿，该股报39.200港元/股，成交量50.56万股，换手率0.38%，振幅5.33%。康希诺生物股票所在的生物技术行业中，整体涨幅为2.05%。公告显示，康希诺2024年实现营收8.46亿元，同比增加137.01%，净利润为亏损3.79亿元，同比缩窄了74.45%，扣非后净利润亏损为4.41亿元，同比减少了72.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228095307abe00b71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228095307abe00b71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","06185","688185","BK1161","BK1191","BK1574"],"gpt_icon":0},{"id":"2514786488","title":"康希诺生物(06185)发布2024年度业绩快报，归母净亏损3.79亿元，同比收窄74.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514786488","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514786488?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:10","pubTimestamp":1740647456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物(06185)发布2024年度业绩快报，营业总收入8.46亿元(人民币，单位下同)，同比增长137.01%;归属于母公司所有者的净亏损3.79亿元，同比收窄74.45%;基本每股亏损1.53元。报告期内，营业总收入同比增加137.01%，变动主要系：MCV4作为中国市场上唯一的四价流脑结合疫苗，集团通过对其市场的精准布局推动持续放量，产品渗透率不断提升，实现销量快速增长;同时，集团经营受全球公共卫生事件的影响已经基本消除。因此，集团营业收入较去年同期大幅增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06185","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2514735598","title":"康希诺生物业绩快报：2024年营收翻倍增长，疫苗商业化加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2514735598","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514735598?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:05","pubTimestamp":1740647158,"startTime":"0","endTime":"0","summary":"报告期内，集团工作重点主要为推进流脑结合疫苗的商业化进程及非新冠疫苗产品的研发。疫苗研发端，集团持续推进在研管线进展，多款候选产品达成重要里程碑，向产业化、商业化快速迈进。报告期内，管理费用、研发费用同比下降，销售费用率也呈下降趋势。集团在产销协同方面不断优化，资产减值损失较去年同期大幅减少。综上，集团营业收入的大幅增长及经营效率的提升，使得本年度归属于母公司所有者的净亏损同比大幅减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227170558a25613de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227170558a25613de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"康希诺生物业绩快报：2024年营收翻倍增长，疫苗商业化加速推进","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185"],"gpt_icon":0},{"id":"2514820540","title":"康希诺2024年度业绩快报：营收8.46亿元 同比增137.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514820540","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514820540?lang=zh_cn&edition=full","pubTime":"2025-02-27 16:47","pubTimestamp":1740646020,"startTime":"0","endTime":"0","summary":"2月27日，康希诺发布公告，2024年度业绩快报显示，公司实现营业总收入8.46亿元，同比增加137.01%。在亏损方面，归母净利润约亏损3.79亿元；扣除非经常性损益的归母净利润约亏损4.41亿元。基本每股收益为-1.53元，较上年同期的-6.01元有所改善。公告中提到，公司总资产为79.58亿元，同比减少14.6%；归属于母公司的所有者权益为49.1亿元，同比减少6.91%。2024年前三季度，康希诺实现收入5.67亿元，归母净利润-2.22亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271654129894aca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271654129894aca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185","688185"],"gpt_icon":0},{"id":"2514407822","title":"康希诺：2024年净利润亏损3.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514407822","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514407822?lang=zh_cn&edition=full","pubTime":"2025-02-27 16:34","pubTimestamp":1740645240,"startTime":"0","endTime":"0","summary":"2月27日，康希诺生物股份公司发布业绩快报，2024年公司实现营业收入8.46亿元，同比增加137.01%；实现归属于母公司所有者的净利润亏损3.79亿元，上年同期亏损14.82亿元。报告期内。公司持续搭建销售渠道ACYW135群脑膜炎球菌多糖结合疫苗（CRM197 载体）曼海欣®作为中国市场上唯一的四价流脑结合疫苗，市场占有率不断提升，同时公司经营受全球公共卫生事件的影响已经基本消除。因此，公司营业收入较去年同期快速增长，带动了公司经营成果的提升。报告期内，管理费用、研发费用同比下降，销售费用率也呈下降趋势。公司在产销协同方面不断优化，资产减值损失较去年同期大幅减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227163708abdefefc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227163708abdefefc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185"],"gpt_icon":0},{"id":"2514070701","title":"港股异动 | 康希诺生物(06185)再涨超10% DTcP-Hib-MCV4联合疫苗获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514070701","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514070701?lang=zh_cn&edition=full","pubTime":"2025-02-26 13:42","pubTimestamp":1740548554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物再涨超10%，该股昨日收涨近9%。消息面上，康希诺生物日前公布，公司研发的吸附无细胞百(组分)白破b型流感嗜血杆菌(结合)-ACYW135群脑膜炎球菌(结合)联合疫苗已获得中国国家药品监督管理局批准，可以开展相关临床试验。公司指出，目前作为DTcP-Hib-MCV4联合疫苗的组成部分，公司的国内首个脑膜炎球菌四价结合疫苗产品曼海欣已获得药品注册证书并商业化，婴幼儿用DTcP处于III期临床阶段，Hib疫苗处于I期临床阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","06185","BK1583","BK1574","BK1576","BK1161","03347","BK1191","BK1515"],"gpt_icon":0},{"id":"2514274410","title":"康希诺生物盘中异动 快速拉升5.09%报39.250港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514274410","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514274410?lang=zh_cn&edition=full","pubTime":"2025-02-26 09:49","pubTimestamp":1740534565,"startTime":"0","endTime":"0","summary":"2025年02月26日早盘09时49分，康希诺生物股票出现波动，股价急速拉升5.09%。截至发稿，该股报39.250港元/股，成交量79.56万股，换手率0.60%，振幅3.61%。资金方面，该股资金流入1757.74万港元，流出981.736万港元。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康希诺生物股票所在的生物技术行业中，整体涨幅为0.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022609492596307fda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022609492596307fda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06185","688185"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":-0.156},{"period":"1month","weight":-0.2111},{"period":"3month","weight":0.0384},{"period":"6month","weight":0.0923},{"period":"1year","weight":0.5302},{"period":"ytd","weight":-0.0984}],"compareEarnings":[{"period":"1week","weight":-0.0949},{"period":"1month","weight":-0.1304},{"period":"3month","weight":0.0848},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.2067},{"period":"ytd","weight":0.031}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.037679},{"month":2,"riseRate":0.833333,"avgChangeRate":0.200805},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050404},{"month":4,"riseRate":0.571429,"avgChangeRate":0.041541},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048095},{"month":6,"riseRate":0.5,"avgChangeRate":0.040455},{"month":7,"riseRate":0.5,"avgChangeRate":0.015509},{"month":8,"riseRate":0,"avgChangeRate":-0.182296},{"month":9,"riseRate":0.666667,"avgChangeRate":0.077531},{"month":10,"riseRate":0.5,"avgChangeRate":0.079945},{"month":11,"riseRate":0.666667,"avgChangeRate":0.127077},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.021788}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}